Approaches to the treatment of disease induced by chikungunya virus.

Abstract	Chikungunya virus, a re-emerging mosquito-borne alphavirus, causes fever, rash and persistent arthralgia/arthritis in humans. Severe outbreaks have occurred resulting in infections of millions of people in Southeast Asia and Africa. Currently there are no antiviral drugs or vaccines for prevention and treatment of chikungunya infections. Herein we report the current status of research on antiviral drugs and vaccines for chikungunya virus infections.
Authors	Jayaram Bettadapura, Lara J Herrero, Adam Taylor, Suresh Mahalingam
Journal	The Indian journal of medical research (Indian J Med Res) Vol. 138 Issue 5 Pg. 762-5 (Nov 2013) ISSN: 0971-5916 [Print] India
PMID	24434329 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References	Antiviral Agents Vaccines
Topics	Aedes (virology) Africa (epidemiology) Alphavirus Infections (drug therapy, epidemiology, immunology, transmission) Animals Antiviral Agents (therapeutic use) Asia, Southeastern Chikungunya Fever Chikungunya virus (immunology, pathogenicity) Disease Outbreaks Fever (drug therapy, epidemiology, virology) Humans Insect Vectors Vaccines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!